First Jiahui International Cell Therapy Summit Forum Held Successfully; Jiahui International Cell Therapy Center Officially Unveiled
Shanghai, October 23, 2026 — The first Jiahui International Cell Therapy Summit Forum, hosted by Jiahui International Hospital and co-organized by the Jiahui Medical Research and Education Group (J-Med), was held today. Bringing together experts for in-depth exchange on cutting-edge advances, standardized clinical application, and international collaboration in cell therapy, the forum also featured the unveiling ceremony of the Jiahui International Cell Therapy Center. Dr. Xiang Naiqiang, Chairman of the Jiahui Medical Management Executive Committee, and Dr. Wu Haishan, President of Jiahui International Hospital, joined Prof. Eric J. Rubin, Editor-in-Chief of The New England Journal of Medicine (NEJM) and a leading global academic figure, together with experts and scholars in cell therapy. The event was live-streamed globally, with physicians, medical students, international healthcare practitioners, patients, and families from 14 countries and regions registering to watch online.

The forum gathered experts from medicine, oncology, cell therapy, and immunology, including: Prof. Eric J. Rubin, Editor-in-Chief of NEJM and Harvard T.H. Chan School of Public Health; Prof. Xu Pengpeng, a lymphoma specialist from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Prof. Xiao Xiuying, Chair of Medical Oncology at Renji Hospital, Shanghai Jiao Tong University School of Medicine; Prof. Xu Huji, Director of Rheumatology and Immunology at the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital); Prof. Hao Siguo, Director of Hematology at Jiahui International Hospital and an expert in hematologic disorders and hematopoietic stem-cell transplantation; and Director Xuan Linli of Medical Oncology at the Jiahui International Cancer Center, among others.
Chairman Xiang Naiqiang noted that, thanks to a large patient population, fast regulatory review, accelerated return of overseas talent, and lower drug-development costs, China's innovative drug R&D and clinical translation capabilities have continued to strengthen in recent years. China has become a hotbed for innovative therapy development and trials and a major contributor to global medical innovation. In June 2026, the world's first solid-tumor CAR-T drug received approval and launched in Shanghai, marking China's landmark transition from technology follower to global contributor in the frontier field of cell therapy. Cell therapy holds broad prospects in oncology and autoimmune disease. With high national medical standards and extensive international cooperation, China is poised to play an even greater role. As China's innovative drugs and frontier therapies reach patients faster, demand from international patients seeking treatment in China keeps growing, and inbound medical travel is shifting from "treatment on the side of a trip" to "dedicated medical travel." Healthcare institutions must further strengthen cross-border clinical service capabilities so that more global patients can access China's innovative medical care conveniently and safely.
Prof. Eric J. Rubin, NEJM Editor-in-Chief and Harvard T.H. Chan School of Public Health, shared that with its large patient population and R&D strength, China has become a global innovation hub for cell therapy. Chinese scholars' publications in top international journals have also grown exponentially — ten years ago, NEJM published only one research article by Chinese authors; this year, more than 20 have been published. It is foreseeable that China will play an increasingly important role in cell therapy.
President Dr. Wu Haishan stated: Over the past nine years, Jiahui International Hospital has provided care for nearly 500,000 visits annually, serving patients from 180 countries and regions. Today, more and more international patients come to China seeking advanced treatment options, which has been a key driver in establishing the Jiahui International Cell Therapy Center. Going forward, the center will strictly comply with national medical regulations and evidence-based medicine principles, while upholding Jiahui's core values — Care, Quality, Impact — and spare no effort to maintain the highest standards in quality control. As a key step in advancing precision medicine, deepening multidisciplinary collaboration, and standardizing the application of frontier therapies, the center will leverage Jiahui International Hospital's comprehensive platform and multidisciplinary capabilities to connect the latest domestic and international research with clinical practice, delivering high-quality care to patients at home and abroad.

Cell therapy has been a major direction of convergence between life sciences and clinical medicine in recent years. As a medical technology using living cells as the therapeutic medium, it treats disease and repairs tissue by replacing or repairing damaged cells, eliminating abnormal cells, or regulating pathological tissue states. In recent years, research and clinical application of cell therapy have advanced continuously in oncology, autoimmune disease, and hematopoietic stem-cell transplantation, making it a key area of global medical innovation and clinical translation.
In the academic session: Prof. Xu Pengpeng focused on "Clinical and Translational Research in Diffuse Large B-Cell Lymphoma"; Prof. Xiao Xiuying presented "Progress and Bottlenecks in Clinical Research of Solid-Tumor Cell Therapy"; Prof. Xu Huji delivered a report on "Clinical Research and Advances in Universal CAR-T and In Vivo CAR-T"; Prof. Hao Siguo introduced "Umbilical Cord Blood Transplantation in Hematologic Malignancies"; and Director Xuan Linli shared "Real-World CAR-T Treatment and Long-Term Infection Management."

In oncology cell therapy, especially CAR-T, the Jiahui International Cancer Center has accumulated extensive clinical experience. In September 2023, the first foreign patient in China treated with axicabtagene ciloleucel (Yescarta) CAR-T was discharged from the center. Since then, the center has provided CAR-T services to patients from Singapore, Hong Kong (China), Russia, Hungary, New Zealand, India, Pakistan, the Maldives, and other countries and regions.
After the world's first solid-tumor CAR-T therapy was approved in China in June 2026, Jiahui became one of the first institutions to deliver the clinical application and treated the world's first foreign patient to receive this therapy. Meanwhile, Jiahui continues to promote international exchange and sharing of clinical experience with Chinese innovative therapies. In May 2026, the Jiahui International Cancer Center delivered an online Specialized training, "Advances in Frontier Oncology Treatment: CAR-T Innovation and Full-Cycle Clinical Management," for more than 360 physicians from Saudi Arabia, systematically introducing the fundamentals of CAR-T clinical management and exchanging on the application prospects of innovative cell therapies.
Looking ahead, the Jiahui International Cell Therapy Center will build on cell therapy regimens already approved within China, tailor them to each patient's condition and indications, and rely on Jiahui International Hospital's multidisciplinary platform to continuously refine the full service pathway — from patient assessment, cell collection, infusion management, and adverse-event monitoring and management, to post-treatment follow-up and revisit. The center will further capitalize on Jiahui's strengths in multilingual service, cross-cultural communication, and international patient management to deliver standardized, continuous, and individualized cell therapy to patients worldwide.



Comments